DDInter1055 DDInter1376
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic [ofloxacin]. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along with other quinolones such as [gatifloxacin] and [moxifloxacin], is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections.[A31453,A190756] Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after.
Ozanimod is a once-daily sphingosine 1-phosphate receptor modulator for the treatment of relapsing Multiple Sclerosis (MS) and inflammatory bowel disease. It was developed by Celgene (now acquired by Bristol-Myers Squibb) and was approved by the FDA on March 26, 2020.[L12573,L12582] The US approval was followed by the approval in Canada on October 2, 2020. In November 2021, ozanimod was also approved by the European Commission for the treatment of adults with relapsing remitting multiple sclerosis.[L39377,L39382] MS is a devastating inflammatory disease that often progresses and causes severe neurological, physical, and cognitive effects. Inflammatory bowel disease also a chronic inflammatory condition and can cause persistent abdominal pain, diarrhea, bloody stools, and vomiting. In clinical trials, Ozanimod has been shown to be well-tolerated and has resulted in a higher decrease in the rate of MS relapses than with intramuscular [interferon beta-1a], a current standard in MS therapy. Studies involving patients with inflammatory bowel disease have also shown promising results.[A189318,A189342]
Levofloxacin {u} (Compound) resembles {v} (Compound) Enoxacin
Levofloxacin {u} (Compound) resembles {v} (Compound) Sparfloxacin
Levofloxacin {u} (Compound) binds {v} (Gene) ABCB1
Levofloxacin {u} (Compound) upregulates {v} (Gene) CPVL
Levofloxacin {u} (Compound) palliates {v} (Disease) chronic obstructive pulmonary disease
Levofloxacin {u} (Compound) is included by {v} (Pharmacologic Class) Quinolones
Levofloxacin {u} (Compound) downregulates {v} (Gene) TRIB3
Levofloxacin {u} (Compound) causes {v} (Side Effect) Dysphagia
Levofloxacin (Compound) resembles Enoxacin (Compound)
Levofloxacin (Compound) resembles Sparfloxacin (Compound)
Levofloxacin (Compound) binds ABCB1 (Gene)
Levofloxacin (Compound) upregulates CPVL (Gene)
Levofloxacin (Compound) palliates chronic obstructive pulmonary disease (Disease)
Levofloxacin (Compound) is included by Quinolones (Pharmacologic Class)
Levofloxacin (Compound) downregulates TRIB3 (Gene)
Levofloxacin (Compound) causes Dysphagia (Side Effect)